July 25, 2017 09:49 AM EDTUpdated 10:09 AM

Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA

Shehla Shakoor

Managing Director

→ With its shares boosted by news of swelling revenue from its eteplirsen franchise in Duchenne muscular dystrophy, Sarepta has priced shares $SRPT for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA

Shehla Shakoor

Managing Director

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

France stops Valneva's chikungunya vaccine rollout in over 65s after safety issue

Exclusive: Can AI replace animal testing? A new biotech launches to find out

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Sarep­ta rais­ing $325M; Astel­las joins the big mi­gra­tion to Cam­bridge, MA

Managing Director

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA